Beyond (or Back to) Traditional Risk Factors: Preventing Cardiovascular Disease in Patients with Chronic Kidney Disease
Authors: Lawrence J. Appel
Journal: Annals of Internal Medicine (2004)

Editorials6 January 2004Beyond (or Back to) Traditional Risk Factors: Preventing Cardiovascular Disease in Patients with Chronic Kidney DiseaseLawrence J. Appel, MD, MPHLawrence J. Appel, MD, MPHFrom Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD 21205.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-1-200401060-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Patients with chronic kidney disease carry an extraordinarily high risk for cardiovascular disease (CVD). In fact, most patients with chronic kidney disease will die of CVD before reaching end-stage kidney disease (1). A logical starting point for CVD prevention efforts in this population is determining the extent to which traditional CVD risk factors (that is, smoking, blood pressure, diabetes, and hypercholesterolemia) are responsible for the excess risk for CVD. In this issue, Muntner and colleagues (2) highlight the possibility that other risk factors, commonly termed nontraditional risk factors, also contribute to the burden of CVD in this population.The setting ...References1. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al . 1989 Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 13:I80-93. [PMID: 2490833] CrossrefMedlineGoogle Scholar2. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140:9-17. LinkGoogle Scholar3. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al . National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-47. [PMID: 12859163] LinkGoogle Scholar4. Coresh J, Longenecker JC, Miller ER, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9:S24-30. [PMID: 11443765] MedlineGoogle Scholar5. Nygärd O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al . Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995;274:1526-33. [PMID: 7474221] CrossrefMedlineGoogle Scholar6. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, et al . The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods. J Am Soc Nephrol. 2003;14:S148-53. [PMID: 12819321] CrossrefMedlineGoogle Scholar7. Appel LJ, Middleton J, Miller ER, Lipkowitz M, Norris K, Agodoa LY, et al . The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003;14:S166-72. [PMID: 12819323] CrossrefMedlineGoogle Scholar8. Alaupovic P, Heinonen T, Shurzinske L, Black DM. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis. 1997;133:123-33. [PMID: 9258416] CrossrefMedlineGoogle Scholar9. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart. 2003;89:893-6. [PMID: 12860867] CrossrefMedlineGoogle Scholar10. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-5. [PMID: 10411845] CrossrefMedlineGoogle Scholar11. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-57. [PMID: 7563456] CrossrefMedlineGoogle Scholar12. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-22. [PMID: 12387654] CrossrefMedlineGoogle Scholar13. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al . Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904. [PMID: 12928466] CrossrefMedlineGoogle Scholar14. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al . Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-7. [PMID: 12928465] CrossrefMedlineGoogle Scholar15. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;290:932-40. [PMID: 12928471] CrossrefMedlineGoogle Scholar16. Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, et al . Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002;57:327-35. [PMID: 12036190] CrossrefMedlineGoogle Scholar17. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al . Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens. 1997;10:1201-7. [PMID: 9397237] CrossrefMedlineGoogle Scholar18. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, et al . Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407-15. [PMID: 12802026] CrossrefMedlineGoogle Scholar19. for the AASK Study Group. Phillips RA, Appel LJ, Gabriel A. Gassman J, Diurnal patterns of BP in African Americans with hypertensive kidney disease: results from the AASK Cohort Study. Am J Hypertension. 2003;16:99A. CrossrefGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD 21205.Acknowledgments: The author thanks Thomas Erlinger, Jeff Fink, Eliseo Guallar, Edgar Miller, and Jean Marie Ricketts for their insightful comments on draft versions of this editorial.Grant Support: Research grants DK61022 and DK45430 from the National Institute of Diabetes, Digestive and Kidney Diseases.Disclosures: None disclosed.Corresponding Author: Lawrence J. Appel, MD, MPH, Johns Hopkins University, 2024 East Monument Street, Suite 2-600, Baltimore, MD 21205-2223; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Prevalence of Nontraditional Risk Factors for Coronary Heart Disease in Patients with Chronic Kidney Disease Paul Muntner , L. Lee Hamm , John W. Kusek , Jing Chen , Paul K. Whelton , and Jiang He Metrics Cited byWhat Can We Change in Diet and Behaviour in Order to Decrease Carotid Intima-Media Thickness in Patients with Obesity?Plasma fibrinogen and mortality in patients undergoing peritoneal dialysis: a prospective cohort studyCharXgen-Activated Bamboo Charcoal Encapsulated in Sodium Alginate Microsphere as the Absorbent of Uremic Toxins to Retard Kidney Function DeteriorationSoluble CD40 ligand in haemodialysis patients: survival impact and cardiovascular prognostic roleHigh-Density Lipoprotein: Structural and Functional Changes Under Uremic Conditions and the Therapeutic ConsequencesSoluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-upLeft ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized ratsComplement anaphylatoxin C5a contributes to hemodialysis-associated thrombosisNontraditional risk factors for cardiovascular disease in patients with chronic kidney diseasePulse wave velocity in children following renal transplantationThe Relationship Between Nontraditional Risk Factors and Outcomes in Individuals With Stage 3 to 4 CKDPulse Wave Velocity in End-Stage Renal Disease: Influence of Age and Body DimensionsIncreased expression of monocytic angiotensin-converting enzyme in dialysis patients with cardiovascular diseaseEtiology and Management of Hypertension in Chronic Kidney DiseaseChronic Renal Dysfunction as an Independent Risk Factor for the Development of Cardiovascular DiseaseThe epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: A high-risk combination 6 January 2004Volume 140, Issue 1Page: 60-61KeywordsApolipoproteinsBlood pressureC-reactive proteinsCardiovascular diseasesChronic kidney diseaseClinical trialsCoronary heart diseaseKidneysMedical risk factorsObservational studies ePublished: 6 January 2004 Issue Published: 6 January 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...